Figure 3
From: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation
Viability values in bone marrow stromal cells. Difference of viability (XTT test) with respect to controls expressed in percentage in bone marrow stromal cells treated with risedronate (Ris) at different concentrations, with or without NS-398 COX-2 inhibitor (a) and with dexametasone 1 μM (DEX) (b) with or without risedronate (Ris) at different concentrations. The experiments were performed in triplicate.